Natco Pharma Ltd shares continued their sharp fall in Friday's trade after the company recorded a drop in its third-quarter results. The stock plunged 10.80 per cent to hit a 52-week low of Rs 868.25.

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February ...

NATCO Pharma Share Price Today: NATCO Pharma shares today (Feb 12) saw a significant dip of nearly 37% after the company reported a sharp decline in its third-quarter (Q3 FY2025) results. The stock ...

Baker, Donelson, Bearman, Caldwell & Berkowitz shareholder Lauren Brophy Cooper and Alec Wong have entered appearances for Zydus Lifesciences and related companies in a pending patent lawsuit. The ...

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US ...

MUMBAI, June 26 (Reuters) - Natco Pharma Ltd. shares jumped more than 10 percent after it received its first U.S. Food and Drug Administration approval for ondansetron hydrochloride tablets.

Genentech, Inc., Hoffman LA Roche, Inc. Natco Pharma and several Zydus entities were hit with a patent infringement lawsuit on Oct. 31 in New Jersey District Court over their attempts to market ...